1-6 of 6
Zhengzheng Fu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

Lugui Qiu, Weijun Fu, Zhongjun Xia, Zhengzheng Fu, Wenming Chen, Chunkang Chang, Baijun Fang, Gang An, Yongqiang Wei, Zhen Cai, Sujun Gao, Jianyu Weng, Lijuan Chen, Hongmei Jing, Li Fei, Zhuogang Liu, Xiequn Chen, Jing Liu, Yang Yu, Aihua Wang, Yijun Yang, Zhinuan Yu, Kevin Lynch
Journal: Blood
Blood (2021) 138 (Supplement 1): 4770.
https://doi.org/10.1182/blood-2021-145282
Published: 2021
Journal Articles

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

Weijun Fu, Lugui Qiu, Zhongjun Xia, Zhengzheng Fu, Wenming Chen, Chunkang Chang, Baijun Fang, Gang An, Yongqiang Wei, Zhen Cai, Sujun Gao, Jianyu Weng, Lijuan Chen, Hongmei Jing, Li Fei, Zhuogang Liu, Xiequn Chen, Jing Liu, Yang Yu, Aihua Wang, Zhinuan Yu, Yijun Yang, Kevin Lynch
Journal: Blood
Blood (2021) 138 (Supplement 1): 4778.
https://doi.org/10.1182/blood-2021-146784
Published: 2021
Journal Articles

The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China

Jing Li, MD, Li Bao, Zhong-jun Xia, MD, Kaiyang Ding, Bingzong Li, MD PhD, Bing Chen, Zhengzheng Fu, Sili Wang, Wenhao Zhang, MD PhD, Xin Zhou, Luoming Hua, PhD, Wei Yang, Luo Jun, Liang Wang, Tianhong Xu, Yang Yang, Weida Wang, MD, Guolin Wu, Yun Huang, Peng Liu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5592.
https://doi.org/10.1182/blood-2019-130040
Published: 2019
Journal Articles

Ixazomib-Based Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile with Those Reported in Randomized Clinical Trials: A Multi-Center Study in China

Jing Li, MD, Li Bao, Zhong-jun Xia, MD, Sili Wang, Xin Zhou, Kaiyang Ding, Wenhao Zhang, MD PhD, Wei Yang, Bingzong Li, MD PhD, Zhengzheng Fu, Bing Chen, Luoming Hua, PhD, Liang Wang, Luo Jun, Yang Yang, Tianhong Xu, Weida Wang, MD, Yun Huang, Guolin Wu, Peng Liu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3181.
https://doi.org/10.1182/blood-2019-128614
Published: 2019
Journal Articles

PAD Induction Therapy Followed by Autologous Peripheral Blood Stem Cell Transplant (APBSCT) as Upfront Treatment for Myeloma (MM) in Chinese Patients.

Albert Kwok Wai Lie, DePei Wu, Chun Wang, Chor Sang Chim, Raymond Liang, Zhengzheng Fu, Liping Wan
Journal: Blood
Blood (2009) 114 (22): 4367.
https://doi.org/10.1182/blood.V114.22.4367.4367
Published: 2009
Journal Articles

Minoriting Cvtomegalovirus after Hematopoietic Stem Cell Transplantation for Seven Years-a Single Center Study

Xiaojin Wu, Wu Depei, Aining Sun, Xiaowen Tang, Zhengzheng Fu, Xiao MA
Journal: Blood
Blood (2008) 112 (11): 4376.
https://doi.org/10.1182/blood.V112.11.4376.4376
Published: 2008